NOVEL PAN-RAF INHIBITOR BELVARAFENIB AS A PROMISING TARGETED THERAPY FOR BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMAS.

被引：0
|
作者：
Gonzalez, Maxine [1 ]
Lebert, Brittany [1 ]
Campion, Stephani [1 ]
Aguilar-Bonilla, Ana [1 ]
Smith, Amy [1 ]
机构：
[1] Orlando Hlth Arnold Palmer Hosp, Orlando, FL USA
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
10.1093/neuonc/noad073.316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TRLS-13
引用
收藏
页数：1
相关论文
共 26 条
  • [1] INVESTIGATING THE EFFICACY OF BELVARAFENIB, A TYPE II PAN-RAF INHIBITOR, AS A POTENTIAL THERAPEUTIC AGENT TO TREAT PEDIATRIC LOW-GRADE GLIOMAS HARBORINGBRAF FUSIONS
    Lebert, Brittany M.
    Gonzalez-Vega, Maxine
    Jafrani, Ryan
    Aguilar-Bonilla, Ana
    Smith, Amy A.
    NEURO-ONCOLOGY, 2024, 26
  • [2] Increased confidence of radiomics facilitating pretherapeutic differentiation of BRAF-altered pediatric low-grade glioma
    Kudus, Kareem
    Wagner, Matthias W.
    Namdar, Khashayar
    Nobre, Liana
    Bouffet, Eric
    Tabori, Uri
    Hawkins, Cynthia
    Yeom, Kristen W.
    Ertl-Wagner, Birgit B.
    Khalvati, Farzad
    EUROPEAN RADIOLOGY, 2024, 34 (04) : 2772 - 2781
  • [3] Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
    Kim, Tae Won
    Lee, Jeeyun
    Shin, Sang Joon
    Kim, Jin-Soo
    Kim, Yu Jung
    Han, Hye Sook
    Lee, Soo Jung
    Lim, Hyeong-Seok
    Hong, Yoon-hee
    Noh, Young Su
    Kyoung, Yujung
    Han, Oakpil
    Yoon, Jiyeon
    Lim, Jeong Ah
    Kim, Suk Ran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Increased confidence of radiomics facilitating pretherapeutic differentiation of BRAF-altered pediatric low-grade glioma
    Kareem Kudus
    Matthias W. Wagner
    Khashayar Namdar
    Liana Nobre
    Eric Bouffet
    Uri Tabori
    Cynthia Hawkins
    Kristen W. Yeom
    Birgit B. Ertl-Wagner
    Farzad Khalvati
    European Radiology, 2024, 34 : 2772 - 2781
  • [5] PEDIATRIC LOW-GRADE GLIOMAS-RAPID PROGRESSION FOLLOWING DISCONTINUATION OF BRAF/MEK TARGETED THERAPY
    Bruggers, Carol
    Chan, Priya
    Perry, Arie
    Putnam, Angelica
    Linscott, Luke
    Cheshier, Samuel
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [6] TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB
    Nguyen, Tiffany
    McMahon, Kathleen
    Hemenway, Molly
    Levy, Jean Mulcahy
    Foreman, Nicholas
    Dorris, Kathleen
    NEURO-ONCOLOGY, 2020, 22 : 371 - 371
  • [7] TYPE II RAF INHIBITORS INHIBIT BRAF MUTATIONS AND TRUNCATED FUSIONS IN PEDIATRIC LOW-GRADE GLIOMAS
    Kieran, Mark W.
    Sun, Yu
    Pilarz, Catherine
    Calligaris, David
    Chadwick, Emily J.
    Alberta, John A.
    Ramkissoon, Shakti H.
    Ramkissoon, Lori A.
    Garcia, Veronica Matia
    Wilkinson, Kim
    Kane, Michael
    Goumnerova, Liliana
    Chi, Susan N.
    Manley, Peter
    Wright, Karen D.
    Agar, Nathalie Y.
    Ligon, Keith L.
    Beroukhim, Rameen
    Bandopadhayay, Pratiti
    Kannan, Geoffrey
    Segal, Rosalind A.
    Garraway, Levi A.
    Gray, Nathanael S.
    Eck, Michael
    Stiles, Charles D.
    Buhrlage, Sara J.
    NEURO-ONCOLOGY, 2016, 18 : 89 - 89
  • [8] FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.
    Kilburn, Lindsay Baker
    Jabado, Nada
    Franson, Andrea
    Chi, Susan N.
    Fisher, Michael J.
    Hargrave, Darren R.
    Hansford, Jordan R.
    Ziegler, David S.
    Landi, Daniel
    Kang, Hyoung Jin
    Gerber, Nicolas U.
    Yalon-Oren, Michal
    Cornelio, Izzy
    Blackman, Samuel C.
    Cox, Michael Craig
    Witt, Olaf
    Prados, Michael
    Mueller, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway Activation
    Lind, Katherine T.
    Chatwin, Hannah, V
    DeSisto, John
    Coleman, Philip
    Sanford, Bridget
    Donson, Andrew M.
    Davies, Kurtis D.
    Willard, Nicholas
    Ewing, Calvin A.
    Knox, Aaron J.
    Levy, Jean M. Mulcahy
    Gilani, Ahmed
    Green, Adam L.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2021, 80 (12): : 1099 - 1107
  • [10] A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors
    Cassier, P.
    Mehnert, J. M.
    Kim, R.
    Chmielowski, B.
    Millward, M.
    Perez, C. A.
    Gonzalez Cao, M.
    Gambardella, V.
    Mckean, M.
    Brose, M. S.
    Xing, Y.
    Long, G. V.
    Kelly, A.
    Lee, G.
    Severson, P.
    Williams, R.
    Marqueste, C. Gaudy
    ANNALS OF ONCOLOGY, 2024, 35 : S491 - S492
123